Literature DB >> 16166413

Caregiver assessment of patients' depression in Alzheimer disease: longitudinal analysis in a drug treatment study.

Paul B Rosenberg1, Michelle M Mielke, Constantine G Lyketsos.   

Abstract

OBJECTIVE: Caregiver input is important in the assessment of depression in Alzheimer disease (AD), but depression and subjective burden can bias this input.
METHODS: In a 12-week, controlled, clinical trial of sertraline in depressed AD patients, authors correlated caregiver mood and subjective burden on several patient mood measures, incorporating varied degrees of caregiver input.
RESULTS: Caregiver variables accounted for up to 33% of the variance in patient mood ratings. Caregiver depression and burden decreased regardless of treatment assignment.
CONCLUSION: Caregiver depression and burden affect their rating of AD patients' mood, but the majority of variance is due to patient characteristics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166413     DOI: 10.1176/appi.ajgp.13.9.822

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  9 in total

Review 1.  Depression in cognitive impairment.

Authors:  Laurel D Pellegrino; Matthew E Peters; Constantine G Lyketsos; Christopher M Marano
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

2.  Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2.

Authors:  Crystal V Flynn Longmire; Lea T Drye; Constantine E Frangakis; Barbara K Martin; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2014-01       Impact factor: 4.105

3.  Neuropsychiatric Symptoms in Dementia: Overview and Measurement Challenges.

Authors:  C G Lyketsos
Journal:  J Prev Alzheimers Dis       Date:  2015-09

4.  Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease.

Authors:  Naama Levy-Cooperman; Amer M Burhan; Shahryar Rafi-Tari; Maggie Kusano; Joel Ramirez; Curtis Caldwell; Sandra E Black
Journal:  J Psychiatry Neurosci       Date:  2008-05       Impact factor: 6.186

5.  Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.

Authors:  Paul B Rosenberg; Lea T Drye; Anton P Porsteinsson; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Lon S Schneider; David M Shade; Daniel Weintraub; Jeffery Newell; Jerome Yesavage; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2015-08-25       Impact factor: 3.878

6.  The Brazilian version of the Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity in dementia.

Authors:  Florindo Stella; Orestes Vicente Forlenza; Jerson Laks; Larissa Pires de Andrade; Michelle A Ljubetic Avendaño; Elisandra Villela Gasparetto Sé; João de Castilho Cação; Constantine G Lyketsos; Kate de Medeiros
Journal:  Int Psychogeriatr       Date:  2013-06-14       Impact factor: 3.878

7.  Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force.

Authors:  M Sano; M Soto; M Carrillo; J Cummings; S Hendrix; J Mintzer; A Porsteinsson; P Rosenberg; L Schneider; J Touchon; P Aisen; B Vellas; C Lyketsos
Journal:  J Prev Alzheimers Dis       Date:  2018

8.  Self-, collateral- and clinician assessment of depression in persons with cognitive impairment.

Authors:  Mohit P Chopra; Jan R Sullivan; Zachary Feldman; Reid D Landes; Cornelia Beck
Journal:  Aging Ment Health       Date:  2008-11       Impact factor: 3.658

Review 9.  Assessment of neuropsychiatric symptoms in dementia: toward improving accuracy.

Authors:  Florindo Stella
Journal:  Dement Neuropsychol       Date:  2013 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.